一项100例肩袖肌腱病前瞻性研究显示肩峰下滑囊炎与超声引导下皮质类固醇注射疗效无相关性
单中心前瞻性研究纳入100例肩袖肌腱病患者,均接受超声引导下滑囊内注射倍他米松1 ml,3个月时60%(54/100)为良好反应者。伴与不伴肩峰下滑囊炎两组良好反应率无差异(p=0.6),随访期间牛津肩评分随时间改善,未发现与良好结局显著相关的超声或X线特征。
要点
- 肩峰下滑囊炎的存在与否不影响肩袖肌腱病患者超声引导下皮质类固醇注射后3个月的临床结局(p=0.6)。
- 超声引导下肩峰下皮质类固醇注射使60%(54/100)的肩袖肌腱病患者获得显著改善。
- 除反映工作满意度的Minnesota评分外,未发现与成功结局相关的基线临床、X线或超声特征。
核心结论
- 肩峰下滑囊炎的存在不影响肩袖肌腱病患者肩峰下注射后3个月的临床结局。
- 就患者管理而言,寻找滑囊炎的超声征象似乎与注射指征无关。
研究设计与样本
- 单中心前瞻性研究,纳入100例因肩袖肌腱病转诊接受肩峰下注射的患者。
- 基线时所有患者接受超声引导下滑囊内注射倍他米松1 ml。
- 主要终点为术后3个月疼痛缓解,良好反应者定义为视觉模拟量表疼痛下降超过30%。
- 次要终点包括以牛津肩评分(OSS)评估的功能恢复及6周时的临床成功。
- 还探索了良好临床反应与超声或X线特征等其他因素的关联。
关键影像表现/征象
- 100例患者中49例存在肩峰下滑囊炎。
- 未发现任何超声或X线特征与良好临床结局显著相关。
诊断标准与关键数值
- 良好反应者定义为术后3个月视觉模拟量表疼痛下降超过30%。
- 3个月时60%的患者(54/100)为良好反应者。
- 伴滑囊炎组与不伴滑囊炎组的良好反应率无差异(p=0.6)。
- 随访期间牛津肩评分随时间改善,无论是否存在滑囊炎。
- 除反映工作满意度的Minnesota评分外,未发现与成功结局相关的基线临床、X线或超声特征。
临床应用与阅片要点
- 作者认为,寻找滑囊炎的超声征象似乎与肩峰下皮质类固醇注射的指征无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The objective of this study was to determine whether the presence of subacromial bursitis in patients with rotator cuff tendinopathy (RCT) was associated with a better outcome after ultrasound (US)-guided subacromial corticosteroid injection.
METHODS: A single-center prospective study was performed including patients referred for subacromial injection to manage RCT. At baseline, all patients received an US-guided intra-bursal injection of betamethasone (1 ml). The primary endpoint was reduced pain 3 months (M3) after the procedure: a good responder was defined by a decrease in Visual Analogue Scale pain of more than 30%. Secondary endpoints included functional recovery assessed by the Oxford Shoulder Score (OSS) and clinical success at 6 weeks (W6). We also explored the association between good clinical response and other factors, such as US or X-ray features.
RESULTS: One hundred patients were included and 49 presented with subacromial bursitis. At M3, 60% of patients (54/100) were considered good responders. The rate of good responders did not differ between the bursitis and non-bursitis groups (p = 0.6). During follow-up, OSS improved over time whether bursitis was present or not. We did not find any US or X-ray features significantly associated with a favorable clinical outcome.
CONCLUSION: The presence of subacromial bursitis did not influence clinical outcomes at 3 months post-subacromial injection in patients suffering from RCT.
CLINICAL RELEVANCE STATEMENT: The presence of subacromial bursitis did not influence clinical outcomes at 3 months post-subacromial corticosteroid injection in patients with rotator cuff tendinopathy. For patient management, looking for ultrasonographic signs of bursitis does not appear relevant for the indication of the injection.
KEY POINTS: • Ultrasound-guided subacromial corticosteroid injections led to a significant improvement in 60% of patients suffering from rotator cuff tendinopathy. • The presence of subacromial bursitis was not associated with better improvement at 3 months post-injection. • Except for the Minnesota score referring to job satisfaction, we did not find any baseline clinical, X-ray, or ultrasound characteristics associated with a successful outcome.
引用
- Metayer B, Fouasson-Chailloux A, Le Goff B, et al. A prospective study of 100 patients with rotator cuff tendinopathy showed no correlation between subacromial bursitis and the efficacy of ultrasound-guided corticosteroid injection. Eur Radiol. 2023. PMID: 37540320. doi:10.1007/s00330-023-09989-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。